Table 2.
Patient demographics and characteristics in Cohort 2.
| Original data | Data after propensity score matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Combination therapy n = 89 | Monotherapy n = 67 | P | SMD | Combination therapy n = 35 | Monotherapy n = 35 | P | SMD | ||
| Age (years) | Years, median (range) | 62 (35–79) | 68 (48–86) | < 0.01 | 0.57 | 63 (40–79) | 64 (49–79) | 0.23 | 0.36 |
| Sex, n (%) | Male | 49 (55) | 42 (63) | 0.34 | 0.16 | 20 (57) | 23 (66) | 0.46 | 0.18 |
| Female | 40 (45) | 25 (37) | 15 (43) | 12 (34) | |||||
| ECOG PS, n (%) | 0 | 67 (75) | 43 (64) | 0.02 | 0.49 | 26 (74) | 27 (77) | 0.53 | 0.27 |
| 1 | 22 (25) | 17 (25) | 9 (26) | 7 (20) | |||||
| ≥ 2 | 0 | 7 (11) | 0 | 1 (3) | |||||
| Previous surgical resection, n (%) | 11 (12) | 8 (12) | 0.94 | 0.01 | 5 (14) | 5 (14) | 1.00 | < 0.01 | |
| Tumor location, n (%) | Head | 40 (45) | 34 (51) | 0.45 | 0.21 | 14 (40) | 19 (54) | 0.33 | 0.36 |
| Body | 31 (35) | 17 (25) | 10 (29) | 10 (29) | |||||
| Tail | 18 (20) | 16 (24) | 11 (31) | 6 (17) | |||||
| Histology, n (%) | Adenocarcinoma | 79 (89) | 57 (85) | 0.79 | 0.11 | 31 (89) | 30 (86) | 0.92 | 0.10 |
| Others | 1 (1) | 1 (1) | 1 (3) | 1 (3) | |||||
| Unknown | 9 (10) | 9 (13) | 3 (9) | 4 (11) | |||||
| Number of metastatic sites, n (%) | 1 | 57 (64) | 40 (60) | 0.58 | 0.09 | 19 (54) | 23 (66) | 0.33 | 0.24 |
| ≥ 2 | 32 (36) | 27 (40) | 16 (46) | 12 (34) | |||||
| Ascites, n (%) | 17 (19) | 12 (18) | 0.85 | 0.03 | 5 (14) | 4 (11) | 0.72 | 0.09 | |
| Albumin level (g/dL) | Median (range) | 3.9 (2.8–4.8) | 3.9 (2.5–4.7) | 0.31 | 0.22 | 3.9 (2.8–4.5) | 3.9 (2.5–4.4) | 0.72 | 0.11 |
| LDH level (U/L) | Median (range) | 181 (99–923) | 169 (122–328) | 0.04 | 0.30 | 177 (147–923) | 167 (122–328) | 0.09 | 0.44 |
| CRP level (mg/dL) | Median (range) | 0.24 (0.01–8.88) | 0.38 (0.01–7.26) | 0.85 | 0.14 | 0.28 (0.01–8.88) | 0.14 (0.02–6.60) | 0.28 | 0.15 |
| CEA level (ng/mL) | Median (range) | 6.0 (0.4–364.2) | 4.1 (0.7–626.6) | 0.88 | 0.25 | 6.0 (0.4–304.5) | 3.4 (0.7–336.7) | 0.50 | 0.18 |
| CA19-9 level (U/mL) | Median (range) | 987 (1–6,554,100) | 1232 (1–590,340) | 0.84 | 0.15 | 891 (1–1,242,609) | 717 (2–96,693) | 0.25 | 0.26 |
| Neutrophil-to-lymphocyto ratio | Median (range) | 1.96 (0.09–7.57) | 2.31 (0.59–15.17) | 0.10 | 0.39 | 2.64 (0.65–7.57) | 1.91 (0.59–15.00) | 0.54 | 0.09 |
| First-line chemotherapy, n (%) | FFX | 66 (74) | 13 (29) | < 0.01 | 1.31 | 12 (34) | 12 (34) | 1.00 | < 0.01 |
| GnP | 23 (26) | 54 (81) | 23 (66) | 23 (66) | |||||
| Withdrawal reason, n (%) | Progression | 83 (93) | 54 (81) | 0.057 | 0.38 | 35 (100) | 26 (74) | < 0.01 | 0.83 |
| Adverse events | 5 (6) | 11 (16) | 0 | 7 (20) | |||||
| Others | 1 (1) | 2 (3) | 0 | 2 (6) | |||||
| Duration of first-line chemotherapy | Months, median (range) | 5.4 (0.4–30.8) | 5.8 (0.4–18.8) | 0.61 | 0.03 | 5.8 (0.9–30.8) | 5.8 (0.4–10.6) | 0.31 | 0.45 |